Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study
Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, Lucía Romero Pinel, Virginia Delgado Gil, Eduar · 2026
Read Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study by Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, Lucía Romero Pinel, Virginia Delgado Gil, Eduar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473779.txt.
Description
Background:Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited.Objective:To assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting.Design:Non-interventional/observational, retrospective, multicenter study (28 centers).
Catalog record
| CREATOR | Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, Lucía Romero Pinel, Virginia Delgado Gil, Eduar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |